MARKET

IMTX

IMTX

Immatics N.V.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.00
+0.28
+2.61%
Closed 19:39 05/17 EDT
OPEN
10.77
PREV CLOSE
10.72
HIGH
11.21
LOW
10.77
VOLUME
81.18K
TURNOVER
--
52 WEEK HIGH
18.42
52 WEEK LOW
8.67
MARKET CAP
903.05M
P/E (TTM)
-2.4154
1D
5D
1M
3M
1Y
5Y
Immatics Q1 Sales $8.70M Up From $8.20M YoY
Immatics (NASDAQ:IMTX) reported $8.70 million in sales this quarter. This is a 6.10 percent increase over sales of $8.20 million the same period last year.
Benzinga · 19m ago
Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAME
Immatics’ second TCR Bispecifics program IMA402 demonstrates tumor cell killing in vitro and complete regressions of established tumors in an in vivo tumor modelIMA402 targets an Immatics-validated peptide derived from PRAME, one of the most frequently exp...
GlobeNewswire · 6d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers
Benzinga · 05/04 20:33
What Kind Of Investors Own Most Of Immatics N.V. (NASDAQ:IMTX)?
Simply Wall St. · 04/03 10:41
Leerink Partners Reaffirms Their Buy Rating on Immatics (IMTX)
In a report issued on March 30, Jonathan Chang from Leerink Partners maintained a Buy rating on Immatics (IMTX), with a price target of $26.00. The
SmarterAnalyst · 04/01 09:46
JMIA, WATT, CAN and SEEL among premarket gainers
VirTra VTSI +56% on Q4 results.Color Star Technology Co., Ltd. CSCW +56% as company to develop NFT.Performant Financial Corporation (PFMT) +26%.Monopar Therapeutics MNPR +18% on preclinical update of its uPA.Moleculin Biotech MBRX +18% on FDA's fast track ...
Seekingalpha · 03/30 12:29
The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 29)
Benzinga · 03/30 12:06
Immatics Announces Full Year 2020 Financial Results and Corporate Update
Phase 1a data update from clinical ACTengine® programs demonstrated first anti-tumor activity at early phases of dose escalation in heavily pre-treated solid cancer patients Enrollment across clinical ACTengine® IMA200 trial series continues to scale up Ca...
GlobeNewswire · 03/30 12:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IMTX. Analyze the recent business situations of Immatics N.V. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IMTX stock price target is 24.17 with a high estimate of 30.21 and a low estimate of 19.13.
EPS
Institutional Holdings
Institutions: 69
Institutional Holdings: 18.93M
% Owned: 23.06%
Shares Outstanding: 82.10M
TypeInstitutionsShares
Increased
7
286.13K
New
12
1.25M
Decreased
11
781.29K
Sold Out
8
1.88M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About IMTX
Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.

Webull offers kinds of Immatics NV stock information, including NASDAQ:IMTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMTX stock methods without spending real money on the virtual paper trading platform.